These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

648 related articles for article (PubMed ID: 21642543)

  • 1. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
    Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C
    J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice.
    Zoja C; Locatelli M; Pagani C; Corna D; Zanchi C; Isermann B; Remuzzi G; Conway EM; Noris M
    J Immunol; 2012 Oct; 189(7):3661-8. PubMed ID: 22942429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement.
    Locatelli M; Buelli S; Pezzotta A; Corna D; Perico L; Tomasoni S; Rottoli D; Rizzo P; Conti D; Thurman JM; Remuzzi G; Zoja C; Morigi M
    J Am Soc Nephrol; 2014 Aug; 25(8):1786-98. PubMed ID: 24578132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mouse model for hemolytic uremic syndrome induced by outer membrane vesicles of Escherichia coli O157:H7.
    Kim SH; Lee YH; Lee SH; Lee SR; Huh JW; Kim SU; Chang KT
    FEMS Immunol Med Microbiol; 2011 Dec; 63(3):427-34. PubMed ID: 22029600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome.
    Ståhl AL; Sartz L; Karpman D
    Blood; 2011 May; 117(20):5503-13. PubMed ID: 21447825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).
    Exeni RA; Fernandez-Brando RJ; Santiago AP; Fiorentino GA; Exeni AM; Ramos MV; Palermo MS
    Pediatr Nephrol; 2018 Nov; 33(11):2057-2071. PubMed ID: 29372302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.
    Zoja C; Buelli S; Morigi M
    Pediatr Nephrol; 2019 Mar; 34(3):379-388. PubMed ID: 29214442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome.
    Arvidsson I; Ståhl AL; Hedström MM; Kristoffersson AC; Rylander C; Westman JS; Storry JR; Olsson ML; Karpman D
    J Immunol; 2015 Mar; 194(5):2309-18. PubMed ID: 25637016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome.
    Polito MG; Kirsztajn GM
    J Bras Nefrol; 2010; 32(3):303-15. PubMed ID: 21103695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shiga Toxin 2 Triggers C3a-Dependent Glomerular and Tubular Injury through Mitochondrial Dysfunction in Hemolytic Uremic Syndrome.
    Buelli S; Locatelli M; Carminati CE; Corna D; Cerullo D; Imberti B; Perico L; Brigotti M; Abbate M; Zoja C; Benigni A; Remuzzi G; Morigi M
    Cells; 2022 May; 11(11):. PubMed ID: 35681450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family.
    Poolpol K; Orth-Höller D; Speth C; Zipfel PF; Skerka C; de Córdoba SR; Brockmeyer J; Bielaszewska M; Würzner R
    Mol Immunol; 2014 Mar; 58(1):77-84. PubMed ID: 24317278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury.
    Ozaki M; Kang Y; Tan YS; Pavlov VI; Liu B; Boyle DC; Kushak RI; Skjoedt MO; Grabowski EF; Taira Y; Stahl GL
    Kidney Int; 2016 Oct; 90(4):774-82. PubMed ID: 27378476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes.
    Geelen JM; van der Velden TJ; Te Loo DM; Boerman OC; van den Heuvel LP; Monnens LA
    Nephrol Dial Transplant; 2007 Mar; 22(3):749-55. PubMed ID: 17127697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement in typical hemolytic uremic syndrome.
    Orth D; Würzner R
    Semin Thromb Hemost; 2010 Sep; 36(6):620-4. PubMed ID: 20865638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.
    Ake JA; Jelacic S; Ciol MA; Watkins SL; Murray KF; Christie DL; Klein EJ; Tarr PI
    Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1.
    Zoja C; Angioletti S; Donadelli R; Zanchi C; Tomasoni S; Binda E; Imberti B; te Loo M; Monnens L; Remuzzi G; Morigi M
    Kidney Int; 2002 Sep; 62(3):846-56. PubMed ID: 12164866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression, in vitro.
    Louise CB; Obrig TG
    Microvasc Res; 1994 May; 47(3):377-87. PubMed ID: 8084301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet thrombus formation in eHUS is prevented by anti-MBL2.
    Kushak RI; Boyle DC; Rosales IA; Ingelfinger JR; Stahl GL; Ozaki M; Colvin RB; Grabowski EF
    PLoS One; 2019; 14(12):e0220483. PubMed ID: 31881024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin.
    Zanchi C; Zoja C; Morigi M; Valsecchi F; Liu XY; Rottoli D; Locatelli M; Buelli S; Pezzotta A; Mapelli P; Geelen J; Remuzzi G; Hawiger J
    J Immunol; 2008 Jul; 181(2):1460-9. PubMed ID: 18606701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of complement in enterohemorrhagic Escherichia coli-Induced hemolytic uremic syndrome.
    Orth-Höller D; Würzner R
    Semin Thromb Hemost; 2014 Jun; 40(4):503-7. PubMed ID: 24799304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.